Cimetidine-Based Cationic Amphiphiles for In Vitro Gene Delivery Targetable to Colon Cancer

Area of Science:

• Biochemistry
• Nanotechnology
• Oncology

Background:

• Cimetidine, a histamine-2 (H2) receptor antagonist, exhibits anticancer properties.
• Gene delivery systems are crucial for targeted cancer therapy.

Purpose of the Study:

• To design and synthesize novel cationic lipids (Toc-Cim and Chol-Cim) incorporating cimetidine for gene delivery.
• To evaluate the efficacy and safety of these lipoplexes for colon cancer gene therapy.

Main Methods:

• Synthesis of Toc-Cim and Chol-Cim lipids with cimetidine head groups and tocopherol/cholesterol moieties.
• Liposome and lipoplex formulation with DOPE and p53 gene.
• In vitro evaluation of physicochemical properties, DNA binding, cytotoxicity, cellular uptake, and transfection efficiency in colon cancer cells (CT-26).

Main Results:

• Toc-Cim and Chol-Cim lipoplexes exhibited optimal size and surface charge for transfection.
• Complete DNA binding was observed at all formulated N/P ratios with minimal cytotoxicity.
• Toc-Cim lipoplexes showed significantly higher transfection efficacy, cellular uptake, and p53-mediated apoptotic cell death in CT-26 cells compared to Chol-Cim.
• Both lipid formulations demonstrated excellent serum compatibility.

Conclusions:

• Toc-Cim is a secure and effective cationic lipid-based transfection agent for colon cancer gene delivery.
• The study highlights the potential of cimetidine-modified lipids in targeted cancer gene therapy.
• Further investigation into Toc-Cim for therapeutic gene delivery is warranted.